Option Investor
Newsletter

ADDITIONAL SPREAD FOR OUR RECOMMENDED LIST

HAVING TROUBLE PRINTING?
Printer friendly version

We are recommending the following put credit spread
to our recommended list.

CELG - Celgene Corporation
engages in the discovery, development, and commercialization of
therapies designed to treat cancer and immunological diseases
through regulation of cellular, genomic, and proteomic targets.
Its lead product, THALOMID, is used for the treatment of acute
cutaneous manifestations of moderate to severe erythema nodosum
leprosum, and as maintenance therapy to prevent and suppress cutaneous
manifestation recurrences.

CELG $59.69

SELL LQH-WK CELG NOV 55 PUT CREDIT = $0.40
BUY LQH-WJ CELG NOV 50 PUT DEBIT = $0.10
NET CREDIT = $0.30

INITIAL "NET- CREDIT TARGET= $0.30 or $30.00
POTENTIAL PROFIT (x 10 CONTRACTS @ $0.30 = $300.00
MARGIN REQUIRE. (x 10 CONTRACTS $4,700.00
RETURN ON INVESTMENT= 6.38%
EXIT Strategy IF NET DEBIT = $1.00

Monthly Cash Machine Newsletter Archives